Literature DB >> 28751563

Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.

Elisa ten Hacken1, Maria Gounari2,3, Jaap Willem Back4, Ekaterina Shimanovskaya4, Lydia Scarfò2, Ekaterina Kim5, Jared Burks5, Maurilio Ponzoni2, Giuseppe Alvise Ramirez2, William G Wierda5, Zeev Estrov5, Michael J Keating5, Alessandra Ferrajoli5, Kostas Stamatopoulos3, Paolo Ghia2, Jan A Burger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28751563      PMCID： PMC5622869          DOI： 10.3324/haematol.2017.169102

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  27 in total

1.  Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia.

Authors:  Stefano Molica; Giovanna Digiesi; Giovanni D'Arena; Rosanna Mirabelli; Anna Antenucci; Laura Conti; Massimo Gentile; Pellegrino Musto; Antonino Neri; Fortunato Morabito
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

2.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

Authors:  Anna Lanemo Myhrinder; Eva Hellqvist; Ekaterina Sidorova; Anita Söderberg; Helen Baxendale; Charlotte Dahle; Kerstin Willander; Gerard Tobin; Eva Bäckman; Ola Söderberg; Richard Rosenquist; Sohvi Hörkkö; Anders Rosén
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

3.  Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation.

Authors:  Rosa Catera; Gregg J Silverman; Katerina Hatzi; Till Seiler; Sebastien Didier; Lu Zhang; Maxime Hervé; Eric Meffre; David G Oscier; Helen Vlassara; R Hal Scofield; Yifang Chen; Steven L Allen; Jonathan Kolitz; Kanti R Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2008-09-25       Impact factor: 6.354

4.  Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Valeria Spina; Riccardo Bomben; Silvia Rasi; Michele Dal-Bo; Alessio Bruscaggin; Francesca Maria Rossi; Sara Monti; Massimo Degan; Carmela Ciardullo; Roberto Serra; Antonella Zucchetto; Josep Nomdedeu; Pietro Bulian; Alberto Grossi; Francesco Zaja; Gabriele Pozzato; Luca Laurenti; Dimitar G Efremov; Francesco Di-Raimondo; Roberto Marasca; Francesco Forconi; Giovanni Del Poeta; Gianluca Gaidano; Valter Gattei
Journal:  Blood       Date:  2013-05-01       Impact factor: 22.113

5.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

6.  Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

Authors:  Charles C Chu; Rosa Catera; Katerina Hatzi; Xiao-Jie Yan; Lu Zhang; Xiao Bo Wang; Henry M Fales; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

7.  Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Authors:  Lesley-Ann Sutton; Emma Young; Panagiotis Baliakas; Anastasia Hadzidimitriou; Theodoros Moysiadis; Karla Plevova; Davide Rossi; Jana Kminkova; Evangelia Stalika; Lone Bredo Pedersen; Jitka Malcikova; Andreas Agathangelidis; Zadie Davis; Larry Mansouri; Lydia Scarfò; Myriam Boudjoghra; Alba Navarro; Alice F Muggen; Xiao-Jie Yan; Florence Nguyen-Khac; Marta Larrayoz; Panagiotis Panagiotidis; Nicholas Chiorazzi; Carsten Utoft Niemann; Chrysoula Belessi; Elias Campo; Jonathan C Strefford; Anton W Langerak; David Oscier; Gianluca Gaidano; Sarka Pospisilova; Frederic Davi; Paolo Ghia; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

8.  Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Authors:  Panagiotis Baliakas; Anastasia Hadzidimitriou; Lesley-Ann Sutton; Eva Minga; Andreas Agathangelidis; Michele Nichelatti; Athina Tsanousa; Lydia Scarfò; Zadie Davis; Xiao-Jie Yan; Tait Shanafelt; Karla Plevova; Yorick Sandberg; Fie Juhl Vojdeman; Myriam Boudjogra; Tatiana Tzenou; Maria Chatzouli; Charles C Chu; Silvio Veronese; Anne Gardiner; Larry Mansouri; Karin E Smedby; Lone Bredo Pedersen; Kirsten van Lom; Véronique Giudicelli; Hana Skuhrova Francova; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Lefteris Angelis; Achilles Anagnostopoulos; Marie-Paule Lefranc; Monica Facco; Livio Trentin; Mark Catherwood; Marco Montillo; Christian H Geisler; Anton W Langerak; Sarka Pospisilova; Nicholas Chiorazzi; David Oscier; Diane F Jelinek; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Richard Rosenquist; Paolo Ghia; Kostas Stamatopoulos
Journal:  Lancet Haematol       Date:  2014-11-03       Impact factor: 18.959

9.  Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome.

Authors:  Davide Rossi; Valeria Spina; Michaela Cerri; Silvia Rasi; Clara Deambrogi; Lorenzo De Paoli; Luca Laurenti; Rossana Maffei; Francesco Forconi; Francesco Bertoni; Emanuele Zucca; Claudio Agostinelli; Antonello Cabras; Marco Lucioni; Maurizio Martini; Michele Magni; Silvia Deaglio; Marco Ladetto; Josep F Nomdedeu; Caroline Besson; Antonio Ramponi; Vincenzo Canzonieri; Marco Paulli; Roberto Marasca; Luigi M Larocca; Antonino Carbone; Stefano A Pileri; Valter Gattei; Gianluca Gaidano
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

10.  Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.

Authors:  Larry Mansouri; Lesley-Ann Sutton; Viktor Ljungström; Sina Bondza; Linda Arngården; Sujata Bhoi; Jimmy Larsson; Diego Cortese; Antonia Kalushkova; Karla Plevova; Emma Young; Rebeqa Gunnarsson; Elin Falk-Sörqvist; Peter Lönn; Alice F Muggen; Xiao-Jie Yan; Birgitta Sander; Gunilla Enblad; Karin E Smedby; Gunnar Juliusson; Chrysoula Belessi; Johan Rung; Nicholas Chiorazzi; Jonathan C Strefford; Anton W Langerak; Sarka Pospisilova; Frederic Davi; Mats Hellström; Helena Jernberg-Wiklund; Paolo Ghia; Ola Söderberg; Kostas Stamatopoulos; Mats Nilsson; Richard Rosenquist
Journal:  J Exp Med       Date:  2015-05-18       Impact factor: 14.307
View more
  4 in total

Review 1.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

Review 2.  The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.

Authors:  Elisa Ten Hacken; Maria Gounari; Paolo Ghia; Jan A Burger
Journal:  Leukemia       Date:  2018-12-16       Impact factor: 11.528

3.  The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.

Authors:  Ekaterina Kim; Elisa Ten Hacken; Mariela Sivina; Astrid Clarke; Philip A Thompson; Nitin Jain; Alessandra Ferrajoli; Zeev Estrov; Michael J Keating; William G Wierda; Kapil N Bhalla; Jan A Burger
Journal:  Leukemia       Date:  2019-12-20       Impact factor: 11.528

Review 4.  B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making.

Authors:  Katerina Gemenetzi; Andreas Agathangelidis; Laura Zaragoza-Infante; Electra Sofou; Maria Papaioannou; Anastasia Chatzidimitriou; Kostas Stamatopoulos
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.